ClinicalTrials.gg

Program

HRS-1301

A development code. Also written as “HRS-1301 Tablets” and “HRS-1301 Tablet”.

Its studies are mostly in Hyperlipidemias, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 14, 20255 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine51 open or runningphase 2since Nov 14, 2025Feb 27, 2025none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-1301, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2025First study: phase 1 study in HyperlipidemiasFirst studyNCT06857253 · 84 enrolled · China
  2. Jul 24, 2025Phase 1 study in HyperlipidemiasNCT07097831 · 16 enrolled · China
  3. Nov 14, 2025Phase 2 study in HyperlipidemiasNCT07229937 · 189 planned · China
  4. Dec 19, 2025Phase 1 study in HyperlipidemiasNCT07322016 · 36 enrolled · China
  5. May 20, 2026Phase 1 study in HyperlipidemiasNCT07608705 · 16 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07608705Hyperlipidemias · China1CompletedAug 24, 202616
NCT07322016Hyperlipidemias · China1CompletedAug 4, 202636
NCT07229937Hyperlipidemias · China2RecruitingAug 2026189
NCT07097831Hyperlipidemias · China1CompletedNov 7, 202516
NCT06857253Hyperlipidemias · China1CompletedAug 12, 202584

How it is read

Names in the registry

  • “HRS-1301”, 5 entries
  • “HRS-1301 Tablets”, 2 entries
  • “HRS-1301 Tablet”, 1 entry

Codes read as this program: HRS1301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.